vs

Side-by-side financial comparison of Innventure, Inc. (INV) and Arcadia Biosciences, Inc. (RKDA). Click either name above to swap in a different company.

Arcadia Biosciences, Inc. is the larger business by last-quarter revenue ($901.0K vs $822.0K, roughly 1.1× Innventure, Inc.). Arcadia Biosciences, Inc. runs the higher net margin — -148.3% vs -4593.8%, a 4445.5% gap on every dollar of revenue.

Innventure, Inc. is a business development and commercialization firm that partners with large global corporations to turn their underutilized intellectual property and unused R&D innovations into scalable, high-growth independent businesses. It focuses on sectors including sustainability, advanced materials and life sciences, serving primarily North American and European markets.

Arcadia Biosciences is a publicly traded American agricultural biotechnology headquartered in Davis, California focused on the development of traits to enhance crop quality and productivity. The company is partly owned by Moral Compass Corporation.

INV vs RKDA — Head-to-Head

Bigger by revenue
RKDA
RKDA
1.1× larger
RKDA
$901.0K
$822.0K
INV
Higher net margin
RKDA
RKDA
4445.5% more per $
RKDA
-148.3%
-4593.8%
INV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
INV
INV
RKDA
RKDA
Revenue
$822.0K
$901.0K
Net Profit
$-37.8M
$-1.3M
Gross Margin
-1315.8%
21.4%
Operating Margin
-3859.1%
-152.8%
Net Margin
-4593.8%
-148.3%
Revenue YoY
-25.8%
Net Profit YoY
67.1%
EPS (diluted)
$-0.18
$-0.97

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INV
INV
RKDA
RKDA
Q4 25
$822.0K
$901.0K
Q3 25
$534.0K
$1.3M
Q2 25
$476.0K
$1.5M
Q1 25
$224.0K
$1.2M
Q4 24
$1.2M
Q3 24
$317.0K
$1.5M
Q2 24
$1.3M
Q1 24
$987.0K
Net Profit
INV
INV
RKDA
RKDA
Q4 25
$-37.8M
$-1.3M
Q3 25
$-28.3M
$856.0K
Q2 25
$-84.2M
$-4.5M
Q1 25
$-143.0M
$2.6M
Q4 24
$-4.1M
Q3 24
$-2.2M
$-1.6M
Q2 24
$1.1M
Q1 24
$-2.4M
Gross Margin
INV
INV
RKDA
RKDA
Q4 25
-1315.8%
21.4%
Q3 25
-676.6%
32.1%
Q2 25
-501.1%
43.4%
Q1 25
17.9%
43.2%
Q4 24
31.9%
Q3 24
-145.1%
32.9%
Q2 24
51.5%
Q1 24
52.3%
Operating Margin
INV
INV
RKDA
RKDA
Q4 25
-3859.1%
-152.8%
Q3 25
-5469.1%
-88.5%
Q2 25
-29952.5%
-34.4%
Q1 25
-116606.3%
44.2%
Q4 24
-187.7%
Q3 24
-4313.6%
-114.5%
Q2 24
Q1 24
-160.9%
Net Margin
INV
INV
RKDA
RKDA
Q4 25
-4593.8%
-148.3%
Q3 25
-5305.6%
65.7%
Q2 25
-17694.7%
-306.4%
Q1 25
-63837.9%
216.6%
Q4 24
-334.5%
Q3 24
-697.5%
-104.9%
Q2 24
81.2%
Q1 24
-245.5%
EPS (diluted)
INV
INV
RKDA
RKDA
Q4 25
$-0.18
$-0.97
Q3 25
$-0.51
$0.62
Q2 25
$-1.60
$-3.26
Q1 25
$-3.10
$1.90
Q4 24
$-2.99
Q3 24
$-0.94
$-1.18
Q2 24
$0.78
Q1 24
$-1.78

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INV
INV
RKDA
RKDA
Cash + ST InvestmentsLiquidity on hand
$60.4M
$4.6M
Total DebtLower is stronger
$8.3M
Stockholders' EquityBook value
$204.2M
$4.1M
Total Assets
$599.2M
$6.5M
Debt / EquityLower = less leverage
0.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INV
INV
RKDA
RKDA
Q4 25
$60.4M
$4.6M
Q3 25
$9.1M
$5.9M
Q2 25
$7.0M
$4.4M
Q1 25
$3.2M
Q4 24
$4.2M
Q3 24
$6.6M
Q2 24
$8.1M
Q1 24
$8.5M
Total Debt
INV
INV
RKDA
RKDA
Q4 25
$8.3M
Q3 25
$29.5M
Q2 25
$16.8M
Q1 25
$12.3M
Q4 24
Q3 24
$14.9M
Q2 24
Q1 24
Stockholders' Equity
INV
INV
RKDA
RKDA
Q4 25
$204.2M
$4.1M
Q3 25
$190.8M
$5.4M
Q2 25
$218.6M
$4.5M
Q1 25
$261.5M
$8.9M
Q4 24
$6.2M
Q3 24
$-22.3M
$10.3M
Q2 24
$11.7M
Q1 24
$10.6M
Total Assets
INV
INV
RKDA
RKDA
Q4 25
$599.2M
$6.5M
Q3 25
$556.5M
$8.6M
Q2 25
$556.0M
$7.8M
Q1 25
$660.4M
$13.0M
Q4 24
$13.5M
Q3 24
$55.7M
$15.2M
Q2 24
$17.4M
Q1 24
$16.0M
Debt / Equity
INV
INV
RKDA
RKDA
Q4 25
0.04×
Q3 25
0.15×
Q2 25
0.08×
Q1 25
0.05×
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INV
INV
RKDA
RKDA
Operating Cash FlowLast quarter
$-80.7M
$-861.0K
Free Cash FlowOCF − Capex
$-82.1M
FCF MarginFCF / Revenue
-9987.8%
Capex IntensityCapex / Revenue
172.4%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-139.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INV
INV
RKDA
RKDA
Q4 25
$-80.7M
$-861.0K
Q3 25
$-19.6M
$-257.0K
Q2 25
$-22.1M
$-2.0M
Q1 25
$-14.7M
$-1.6M
Q4 24
$-2.2M
Q3 24
$-1.8M
Q2 24
$-2.5M
Q1 24
$-3.2M
Free Cash Flow
INV
INV
RKDA
RKDA
Q4 25
$-82.1M
Q3 25
$-20.0M
Q2 25
$-22.1M
Q1 25
$-15.6M
Q4 24
Q3 24
Q2 24
$-2.5M
Q1 24
$-3.2M
FCF Margin
INV
INV
RKDA
RKDA
Q4 25
-9987.8%
Q3 25
-3747.8%
Q2 25
-4637.2%
Q1 25
-6970.1%
Q4 24
Q3 24
Q2 24
-188.3%
Q1 24
-326.5%
Capex Intensity
INV
INV
RKDA
RKDA
Q4 25
172.4%
0.0%
Q3 25
82.2%
0.0%
Q2 25
3.2%
0.0%
Q1 25
409.4%
0.0%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.2%
Q1 24
1.3%
Cash Conversion
INV
INV
RKDA
RKDA
Q4 25
Q3 25
-0.30×
Q2 25
Q1 25
-0.61×
Q4 24
Q3 24
Q2 24
-2.31×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons